Livzon Pharmaceutical Group Inc.
Other OTCTotal Valuation
Livzon Pharmaceutical Group Inc. carries a market capitalization of 6.06B, placing it among publicly traded companies globally. Its enterprise value stands at 16.30B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 6.06B |
| Enterprise Value | 16.30B |
Share Statistics
Livzon Pharmaceutical Group Inc. currently has 904.10M shares outstanding.
| Shares Outstanding | 904.10M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Livzon Pharmaceutical Group Inc. trades at a trailing price-to-earnings ratio of 10.15. The price-to-sales ratio is 1.87, and the price-to-book ratio stands at 1.70.
| PE Ratio | 10.15 |
| PS Ratio | 1.87 |
| PB Ratio | 1.70 |
| P/TBV Ratio | 1.57 |
| P/FCF Ratio | 32.10 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Livzon Pharmaceutical Group Inc. trades at an EV/EBITDA multiple of 5.57 and an EV/FCF ratio of 21.83. The EV/Sales ratio of 1.38 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 5.57 provides insight into valuation relative to core operating earnings.
| EV / Sales | 1.38 |
| EV / EBITDA | 5.57 |
| EV / EBIT | 5.57 |
| EV / FCF | 21.83 |
Financial Position
Livzon Pharmaceutical Group Inc. maintains a current ratio of 2.19, meaning it holds 2.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 24.25, indicating elevated leverage, while an interest coverage ratio of 40.49 demonstrates strong ability to service its debt obligations.
| Current Ratio | 2.19 |
| Quick Ratio | 1.43 |
| Debt / Equity | 24.25 |
| Debt / EBITDA | 1.24 |
| Interest Coverage | 40.49 |
Financial Efficiency
Livzon Pharmaceutical Group Inc. posts a return on equity of 17.57 and a return on invested capital of 12.88.
| Return on Equity (ROE) | 17.57 |
| Return on Assets (ROA) | 8.73 |
| Return on Invested Capital (ROIC) | 12.88 |
| Return on Capital Employed (ROCE) | 11.08 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.21 |
Taxes
Over the trailing twelve months, Livzon Pharmaceutical Group Inc. has paid 524.86M in income taxes, reflecting an effective tax rate of 17.35.
| Income Tax | 524.86M |
| Effective Tax Rate | 17.35 |
Stock Price Statistics
Livzon Pharmaceutical Group Inc.'s stock has gained approximately 52.18659% over the past 52 weeks. The 50-day moving average sits at 5.22, while the 200-day moving average is 5.11.
| Beta (5Y) | N/A |
| 52-Week Price Change | 52.18659% |
| 50-Day Moving Average | 5.22 |
| 200-Day Moving Average | 5.11 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Livzon Pharmaceutical Group Inc. generated 11.80B in revenue and converted that into 2.17B in net income, yielding earnings per share of 2.79. EBITDA reached 2.93B, while operating income came in at 2.93B.
| Revenue | 11.80B |
| Gross Profit | 7.73B |
| Operating Income | 2.93B |
| Pretax Income | 3.03B |
| Net Income | 2.17B |
| EBITDA | 2.93B |
| EBIT | 2.93B |
| Earnings Per Share (EPS) | 2.79 |
Balance Sheet
Livzon Pharmaceutical Group Inc. holds 10.61B in cash and equivalents against 3.62B in total debt, resulting in a net debt position of -6.85B. Total book value stands at 12.96B, with working capital of 8.83B providing operational flexibility.
| Cash & Cash Equivalents | 10.61B |
| Total Debt | 3.62B |
| Net Debt | -6.85B |
| Equity (Book Value) | 12.96B |
| Book Value Per Share | 14.45 |
| Working Capital | 8.83B |
Cash Flow
After subtracting -686.72M in capital expenditures, free cash flow totaled -686.72M - equivalent to -0.77 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -686.72M |
| Free Cash Flow | -686.72M |
| FCF Per Share | -0.77 |
Margins
Livzon Pharmaceutical Group Inc. operates with a gross margin of 65.48, reflecting its pricing power and cost economics. The operating margin of 24.79 and net profit margin of 18.40 provide insight into operational efficiency.
| Gross Margin | 65.48 |
| Operating Margin | 24.79 |
| Pretax Margin | 25.64 |
| Profit Margin | 18.40 |
| EBITDA Margin | 24.79 |
Dividends & Yields
The company's payout ratio of 57.48 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 1.81 |
| Dividend Yield | N/A |
| Payout Ratio | 57.48 |
| Shareholder Yield | 14.73 |
| FCF Yield | 3.12 |
Stock Splits
Livzon Pharmaceutical Group Inc.'s most recent stock split took place on December 23, 2019 with a 10:13 split ratio.
| Last Split Date | 12/23/2019 |
| Split Ratio | 10:13 |
Scores
Livzon Pharmaceutical Group Inc. posts an Altman Z-Score of 3.53, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 3.53 |